查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717886

搔癢症藥物市場：2025-2030 年全球預測（治療方法、給藥途徑、適應症、病患概況、分銷管道和最終用戶）

Pruritus Therapeutics Market by Therapy, Route of Administration, Disease Indication, Patient Demographics, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年搔癢症藥物市場價值將達到 59.3 億美元，2025 年將成長至 62.4 億美元，複合年成長率為 5.47%，到 2030 年將達到 81.7 億美元。

主要市場統計數據
基準年2024年 59.3億美元
預計2025年 62.4億美元
預測年份 2030 81.7億美元
複合年成長率（%） 5.47%

近年來，由於生物醫學研究的快速進步以及對導致慢性搔癢的潛在機制的更深入的了解，搔癢症藥物領域發生了重大轉變。從歷史上看，搔癢症的治療主要針對症狀，依靠第一線療法提供暫時的緩解，而沒有解決根本原因。然而，新型治療劑和創新治療模式的融合正在重新定義治療方法。最近的科學進展使得搔癢症的分類更加精細，從而能夠開發針對特定疾病過程的標靶治療。這種不斷發展的格局的特點是臨床創新、患者期望和監管環境的相互作用，所有這些都是為了改善長期忍受持續性搔癢不適的患者的生活品質。隨著醫療保健提供者和決策者越來越意識到搔癢症狀的複雜性及其對各種皮膚病的影響，他們越來越願意投資研究和複雜的臨床策略。此外，技術進步與新型生物製藥的融合正在為一個新時代鋪平道路，這個新時代不僅關注症狀管理，還針對症狀的分子基礎。本摘要概述了推動變革的力量、加深理解的細分見解以及幫助相關人員利用搔癢症藥物範式轉變的策略建議。

不斷變化的市場動態和治療方式的變革

搔癢症藥物市場目前正在經歷一場變革，重新定義治療模式、臨床方法和病患管理方式。開創性的研究和先進的生物技術產品開發正在改變市場動態，迎來以精準醫療和個人化治療方法通訊協定為重點的新一代治療方法。這種變化很大程度上歸功於藥物發現和開發中最尖端科技的整合，這使得能夠根據個別患者情況制定更快、更有針對性的干涉措施。監管機構也在調整其框架以適應更快的核准，進一步刺激該領域的創新。同時，以患者為中心的技術的出現也增加了對治療方法不僅能提供即時緩解，而且還能考慮長期疾病管理和改善護理品質。不斷發展的治療方法，包括新型分子和再利用的藥物，得到了強力的臨床試驗的支持，證明與傳統方法相比，其療效和安全性有所提高。此外，向遠端醫療和數位健康解決方案的轉變正在補充這些新療法的可近性，並確保臨床進步有效地轉化為現實世界的治療結果。隨著市場力量和技術進步不斷重塑治療格局，相關人員越來越需要重新思考傳統的治療模式，並促進策略合作，以在這些重大變化中保持競爭力。

多方面的市場區隔提供了見解

對搔癢症藥物市場的全面分析揭示了細分見解，這對於理解治療策略和患者偏好的細微差別至關重要。透過對多種治療方法的市場進行研究可以發現，治療方法的演變涵蓋了廣泛的選擇，包括抗組織胺、生物製藥、Calcineurin抑制劑、皮質類固醇和免疫抑制劑。每種藥物都有不同的益處並針對瘙癢的不同方面，從而可以製定個性化的治療方案和專門的患者照護。給藥途徑進一步使市場多樣化，因為治療方法有注射劑、口服劑和外用劑，每種方法根據症狀的嚴重程度和性質具有不同的益處。在考慮適應症時，人們專注於過敏性接觸性皮膚炎、異位性皮膚炎、皮膚T細胞淋巴瘤和蕁麻疹，每種適應症都有其自身的挑戰，需要採取針對性的治療方法。由於治療方法是專門為滿足成人、老年和兒科患者的不同需求而設計的，因此患者人口統計數據在塑造市場格局方面也發揮著不可或缺的作用。此外，醫院藥局、網路藥局和零售藥局等通路對治療藥物的取得和採用有重大影響。最終使用者的頻譜包括診所、皮膚病中心、居家醫療機構和醫院，這進一步凸顯了提供針對性干預措施以應對各種臨床和物流挑戰的重要性。對這些細分標準的綜合分析提供了豐富的見解，為策略決策、資本配置和更符合目標病患小組需求的下一代治療方法的開發提供了資訊。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球皮膚病發生率不斷上升
      • 皮膚健康意識增強，早期診斷和治療趨勢
      • 擴大全球醫療保健基礎設施
    • 限制因素
      • 發展中地區對搔癢症的識別和診斷有其局限性
    • 機會
      • 新型止癢藥物研發活動快速增加
      • 搔癢症治療策略的進展
    • 任務
      • 藥品和治療方法核准的嚴格法規結構
  • 市場區隔分析
    • 治療方法：皮質類固醇具有強大的抗發炎特性，越來越受到青睞
    • 最終使用者：診所和皮膚病中心擴大採用搔癢藥物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 搔癢症藥物市場（依療法）

  • 抗組織胺藥
  • 生物製藥
  • Calcineurin抑制劑
  • 皮質類固醇
  • 免疫抑制劑

第7章 搔癢症藥物市場（依給藥途徑）

  • 注射
  • 口服
  • 話題

第8章 搔癢症藥物市場（依疾病適應症）

  • 過敏性接觸性皮膚炎
  • 異位性皮膚炎
  • 皮膚T細胞
  • 麻疹

9. 搔癢症藥物市場（依患者人口統計）

  • 成年患者
  • 老年患者
  • 兒科患者

第10章 搔癢症藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章。搔癢症藥物市場（按最終用戶）

  • 診所
  • 皮膚科中心
  • 居家照護環境
  • 醫院

12. 美國祛癢藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區搔癢症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14.歐洲、中東和非洲搔癢症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics Inc.
  • Eli Lilly and Company
  • EPI Health LLC by Novan, Inc.
  • Escient Pharmaceuticals by Incyte Corporation
  • Evelo Biosciences, Inc.
  • Galderma SA
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • Mirum Pharmaceuticals, Inc.
  • NeRRe Therapeutics Ltd
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-8E22B61932B7

The Pruritus Therapeutics Market was valued at USD 5.93 billion in 2024 and is projected to grow to USD 6.24 billion in 2025, with a CAGR of 5.47%, reaching USD 8.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.93 billion
Estimated Year [2025] USD 6.24 billion
Forecast Year [2030] USD 8.17 billion
CAGR (%) 5.47%

In recent years, the field of pruritus therapeutics has undergone a significant transformation, fueled by rapid advancements in biomedical research and an increasing understanding of the underlying mechanisms that drive chronic itch. Historically, the management of pruritus was largely symptomatic, relying on front-line therapies to offer temporary relief without addressing the fundamental causes. Today, however, a confluence of novel therapeutic agents and innovative treatment paradigms has redefined the approach to care. Recent scientific breakthroughs have enabled a more granular classification of pruritic conditions, permitting the development of targeted therapies that address specific disease processes. This evolving landscape is marked by an interplay between clinical innovation, patient expectations, and regulatory momentum, all leading to improved quality of life for patients who have long endured the discomfort of persistent itch. As healthcare providers and decision-makers increasingly recognize the complexity of pruritus as a symptom and its impact on various dermatological conditions, there is a growing impetus to invest in research and refined clinical strategies. Moreover, the convergence of technological advancement with emerging biologics has paved the way for a new era that not only emphasizes symptom management but also targets the molecular underpinnings of the condition. This introductory summary outlines the forces driving transformation, the segmentation insights that deepen our understanding, and the strategic recommendations poised to help stakeholders capitalize on the shifting paradigms in pruritus therapeutics.

Evolving Market Dynamics and Transformative Shifts in Therapeutics

The market for pruritus therapeutics is currently experiencing transformative shifts that are redefining treatment landscapes, clinical approaches, and patient management practices. Pioneering research and the development of advanced biotechnological products have altered the market dynamics, ushering in a new generation of therapies that focus on precision medicine and personalized treatment protocols. This shift is largely attributable to the integration of cutting-edge technologies in drug discovery and development, which enables faster, more targeted interventions that can be tailored to individual patient profiles. Regulatory bodies have also adapted their frameworks to accommodate expedited approvals, further fueling innovation in the space. Concurrently, the emergence of patient-centric technologies has amplified the demand for therapies that not only provide rapid relief but also account for long-term disease management and improved quality of care. The evolving therapeutic modalities, which include novel molecules and repurposed drugs, are supported by robust clinical trials demonstrating enhanced efficacy and safety profiles compared to traditional approaches. Furthermore, the shift towards telemedicine and digital health solutions has supplemented the accessibility of these novel treatments, ensuring that clinical advances are effectively translated into real-world outcomes. As market forces and technological advancements continue to reshape the therapeutic landscape, stakeholders are increasingly called to reassess traditional treatment models and foster strategic collaborations to remain competitive amid these sweeping changes.

Insights Derived from Multi-Dimensional Market Segmentation

A comprehensive analysis of the pruritus therapeutics market reveals critical segmentation insights that are pivotal for understanding the nuances of treatment strategies and patient preferences. By studying the market across various therapies, it becomes clear that the evolution in treatment modalities spans a range of options including antihistamines, biologics, calcineurin inhibitors, corticosteroids, and immunosuppressants. Each therapeutic category offers distinct benefits and addresses different aspects of pruritic conditions, enabling tailored treatment protocols and specialized patient care. The route of administration further diversifies the market, as treatments are delivered via injectable, oral, and topical formulations, each offering its own set of advantages depending on the severity and nature of the condition. In examining disease indications, significant attention is given to allergic contact dermatitis, atopic dermatitis, cutaneous T-cell lymphoma, and urticaria, with each indication providing unique challenges and requiring customized therapeutic approaches. Patient demographics also play an integral role in shaping the market landscape, as treatment regimens are specifically designed to accommodate the varying needs of adult, geriatric, and pediatric patients. Additionally, distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies greatly influence access to and adoption of therapeutics. The end-user spectrum, which includes clinics, dermatology centers, homecare settings, and hospitals, further underscores the importance of delivering targeted interventions that meet diverse clinical and logistical challenges. These segmentation criteria, when analyzed together, offer a rich tapestry of insights that inform strategic decision-making, funding allocation, and the development of next-generation therapeutic products that are better aligned with the needs of targeted patient groups.

Based on Therapy, market is studied across Antihistamines, Biologics, Calcineurin inhibitors, Corticosteroids, and Immunosuppressant.

Based on Route of Administration, market is studied across Injectable, Oral, and Topical.

Based on Disease Indication, market is studied across Allergic Contact Dermatitis, Atopic Dermatitis, Cutaneous T-cell, and Urticaria.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on End-User, market is studied across Clinics, Dermatology Centers, Homecare Settings, and Hospitals.

Comprehensive Regional Analysis Across Global Markets

Geographical insights into the pruritus therapeutics market offer a deeper understanding of regional variations in clinical practice patterns, regulatory environments, and patient demographics. In the Americas, dynamic market forces are driven by substantial investments in research and development, robust healthcare infrastructure, and a high level of patient awareness regarding modern therapeutic options. These factors have stimulated rapid growth in demand for innovative treatments. Shifting focus to the Europe, Middle East & Africa region, there is a clear emphasis on stringent regulatory standards and a balanced approach between early adoption of new therapies and cautious market integration. This region is known for its meticulous clinical evaluations and a strong inclination towards evidence-based treatment protocols, ensuring that only therapies with proven efficacy and safety profiles gain wider acceptance. In the Asia-Pacific region, a burgeoning middle class and increasing healthcare expenditures have created fertile ground for the uptake of advanced therapeutics. Yet, this region also faces challenges such as disparate healthcare infrastructures, diverse regulatory landscapes, and significant variations in clinical practice that require a more tailored approach to market entry. Taken together, the regional analysis highlights not only the disparities in market maturity and growth potential but also the opportunities for customized strategies that address the unique challenges and strengths inherent in each region. As market stakeholders consider global expansion, these geographical insights will be instrumental in shaping targeted strategies that leverage regional strengths and address localized challenges effectively.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Strategic Company Initiatives

An in-depth examination of the competitive landscape within pruritus therapeutics reveals a spectrum of innovative companies actively driving market evolution. Key players such as AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., and Avior Bio Inc. have carved out significant niches through sustained investments in research and novel therapeutic development. Companies like Bausch Health Companies Inc., Bayer AG, and Cara Therapeutics Inc. have further expanded the market by integrating emerging biologics and specialty drugs into their portfolios, addressing complex clinical challenges inherent in pruritic conditions. The market is also shaped by the robust presence of industry giants such as Eli Lilly and Company, Escient Pharmaceuticals by Incyte Corporation, and GlaxoSmithKline plc, whose expansive reach and continuous innovation underscore the competitive drive in therapeutic advancements. Moreover, players like EPI Health LLC by Novan, Inc., Evelo Biosciences, Inc., and Galderma S.A. are key contributors to developing tailored treatments that meet the diverse needs of patients across different demographics and indications. Strategic initiatives undertaken by firms such as LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, and Mirum Pharmaceuticals, Inc. showcase an unwavering focus on clinical excellence and patient-centric innovations. The market dynamics are further enriched by contributions from NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals, Inc., which continue to drive the pace of technological advancement and therapeutic efficacy. Additionally, companies like Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc., Vanda Pharmaceuticals Inc., and Viatris Inc. actively contribute to a competitive environment that emphasizes collaboration, innovation, and the rapid integration of scientific discoveries into clinical practice. This collective momentum is redefining the strategic landscape, fostering a dynamic ecosystem where relentless innovation and strategic foresight play crucial roles in meeting both current and future market demands.

The report delves into recent significant developments in the Pruritus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., Avior Bio Inc., Bausch Health Companies Inc., Bayer AG, Cara Therapeutics Inc., Eli Lilly and Company, EPI Health LLC by Novan, Inc., Escient Pharmaceuticals by Incyte Corporation, Evelo Biosciences, Inc., Galderma S.A., GlaxoSmithKline plc, LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, Mirum Pharmaceuticals, Inc., NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc, Vanda Pharmaceuticals Inc., and Viatris Inc.. Strategic Recommendations for Thought Leaders in Therapeutics

For industry leaders looking to gain a competitive advantage in the rapidly evolving market of pruritus therapeutics, strategic foresight and operational agility are essential. First and foremost, investment in research and development should be prioritized, with a focus on pioneering therapies that leverage targeted drug delivery systems and precision medicine. Leaders are encouraged to adopt a proactive approach by establishing strategic partnerships with research institutions and clinical centers to expand the scope of innovative treatment modalities. As the market continues to mature, diversification of product portfolios to include both established therapies and emerging biologics will ensure resilience against market fluctuations. In addition, a deep understanding of patient demographics and evolving clinical needs is crucial; engaging in regular stakeholder consultations and feedback loops will facilitate better alignment of treatment strategies with real-world requirements. Emphasizing digital transformation and telehealth solutions can also enhance patient engagement and adherence to therapy regimens while broadening market reach. Regulatory agility remains a key factor, and leaders should strive to maintain transparent communication channels with regulatory authorities to streamline approval processes for novel drugs. Lastly, competitive intelligence, backed by comprehensive market research, should serve as a cornerstone for strategic planning, enabling organizations to anticipate market trends, effectively allocate resources, and seize growth opportunities in an increasingly dynamic environment.

Summative Insights and Forward-Looking Perspectives

In conclusion, the pruritus therapeutics market is at a pivotal juncture where scientific innovation and strategic vision converge to transform patient care. The evolving landscape, driven by breakthrough research and robust segmentation insights, offers a compelling narrative of progress that extends from advanced therapy options to nuanced regional strategies. The formative insights from multi-dimensional segmentation reveal significant opportunities for tailored interventions while detailed competitive analysis underscores the critical role of leading companies in shaping market direction. Moving forward, continued investment in research, technology, and strategic partnerships will be the linchpin of sustained market growth. Stakeholders who embrace agility and innovation are well-positioned to capitalize on emerging trends, optimize resource allocation, and drive improvements in patient outcomes. The body of insights presented not only highlights the current state of pruritus therapeutics but also provides a forward-looking framework for future market explorations, ensuring that the industry remains responsive to evolving clinical landscapes and patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of dermatological conditions globally
      • 5.1.1.2. Rising awareness about skin health and inclination toward early diagnosis & treatment
      • 5.1.1.3. Expansion of healthcare infrastructure globally
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and diagnosis of pruritus in underdeveloped regions
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in research and development activities for the development of novel pruritus drugs
      • 5.1.3.2. Advancements in therapeutic strategies for the treatment of pruritus
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for the approval of drugs and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy: Increasing preference for corticosteroids due to their strong anti-inflammatory properties
    • 5.2.2. End User: Expanding adoption of pruritus-therapeutics in clinics and dermatology centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pruritus Therapeutics Market, by Therapy

  • 6.1. Introduction
  • 6.2. Antihistamines
  • 6.3. Biologics
  • 6.4. Calcineurin inhibitors
  • 6.5. Corticosteroids
  • 6.6. Immunosuppressant

7. Pruritus Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Topical

8. Pruritus Therapeutics Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Allergic Contact Dermatitis
  • 8.3. Atopic Dermatitis
  • 8.4. Cutaneous T-cell
  • 8.5. Urticaria

9. Pruritus Therapeutics Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult Patients
  • 9.3. Geriatric Patients
  • 9.4. Pediatric Patients

10. Pruritus Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Pruritus Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Dermatology Centers
  • 11.4. Homecare Settings
  • 11.5. Hospitals

12. Americas Pruritus Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pruritus Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pruritus Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Maruho Co., Ltd. strengthens its position in dermatological care with launch of innovative pruritus treatment, Mitchga
    • 15.3.2. Galderma's nemolizumab advances in pruritus therapeutics with new global filing acceptances
    • 15.3.3. Incyte's strategic acquisition of Escient to advance first-in-class pruritus therapies in inflammation
    • 15.3.4. FDA approval expands treatment options for PFIC patients with Mirum Pharmaceutical's LIVMARLI's oral solution for pruritus relief
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Asana BioSciences, LLC
  • 3. Astellas Pharma Inc.
  • 4. Avior Bio Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Cara Therapeutics Inc.
  • 8. Eli Lilly and Company
  • 9. EPI Health LLC by Novan, Inc.
  • 10. Escient Pharmaceuticals by Incyte Corporation
  • 11. Evelo Biosciences, Inc.
  • 12. Galderma S.A.
  • 13. GlaxoSmithKline plc
  • 14. LEO Pharma A/S
  • 15. Mallinckrodt plc
  • 16. MC2 Therapeutics A/S
  • 17. Mirum Pharmaceuticals, Inc.
  • 18. NeRRe Therapeutics Ltd
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Regeneron Pharmaceuticals, Inc.
  • 22. Sanofi S.A.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Toray Industries, Inc.
  • 25. Trevi Therapeutics, Inc
  • 26. Vanda Pharmaceuticals Inc.
  • 27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. PRURITUS THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. PRURITUS THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. PRURITUS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. PRURITUS THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PRURITUS THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ALLERGIC CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CUTANEOUS T-CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 286. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024